MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.03
-0.05
-0.82%
After Hours: 6.30 +0.27 +4.48% 16:08 11/14 EST
OPEN
6.10
PREV CLOSE
6.08
HIGH
6.29
LOW
5.94
VOLUME
58.30K
TURNOVER
--
52 WEEK HIGH
17.92
52 WEEK LOW
3.430
MARKET CAP
92.79M
P/E (TTM)
-0.7462
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ONCT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ONCT News

  • Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting
  • Business Wire.6h ago
  • Oncternal Therapeutics to Present at Stifel Healthcare Conference
  • Business Wire.3d ago
  • The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict
  • Benzinga.4d ago
  • Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.4d ago

More

Industry

Biotechnology & Medical Research
-0.05%
Pharmaceuticals & Medical Research
-0.27%

Hot Stocks

Name
Price
%Change

About ONCT

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.
More

Webull offers Oncternal Therapeutics Inc (ONCT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.